CYNK-101 is under clinical development by Celularity and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CYNK-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CYNK-101 overview
CYNK-101 is under development for the treatment of lymphoma and locally advanced unresectable or metastatic HER2/neu positive gastric, gastroesophageal junction (G/GEJ) adenocarcinoma and EGFR+ non-small cell lung cancer and head and neck squamous cell carcinomas. It is administered by infusion. The therapeutic candidate comprises of engineered human placental CD34+ derived NK cell product with genetically modified CD16 variant (CD16VP) using lentivirus. The drug candidates are being developed based on immuno-modulatory placenta-derived allogenic stem cell therapy (IMPACT) technology platform.
See Also:
Celularity overview
Celularity is a biotechnology company that develops and commercializes therapeutics derived from the placenta for autoimmune and degenerative diseases, immuno-oncology, and functional regeneration. The company’s pre-clinical and clinical assets include CAR-T cell receptor and CAR-NK products; and functional regeneration products for wounds, burns, orthopedic, and other surgical indications. It also provides cord blood and placental blood and tissue biosourcing options. Celularity harnesses allogeneic placental cell platform to develop its product portfolio. The company’s products find application in the treatment of acute myeloid leukemia, crohn’s disease, diabetic peripheral neuropathy, and oral and aesthetic tissue repair among others. Celularity is headquartered in Warren, New Jersey, the US.
For a complete picture of CYNK-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
